Current dosing algorithms do not account for genetic and environmental factors for warfarin dose determinations. This study investigated the contribution of age, CYP2C9 and VKORC1 genotype and body-size to warfarin dose requirements. 
Introduction
Warfarin is the most commonly prescribed anticoagulant drug for the prophylaxis and treatment of venous and arterial thromboembolic disorders 1 . The effectiveness and safety of warfarin is critically dependent on maintaining the prothrombin time, expressed as the International Normalised Ratio (INR), within the therapeutic range.
Subgroup analyses of a number of studies have shown a sharp increase in the risk of bleeding when the INR is above the upper limit of the therapeutic range [2] [3] [4] [5] and the risk of thromboembolic events increases when the INR falls below it 4, 6 .
We have previously demonstrated an important contribution by age and CYP2C9 genotype to warfarin dose requirements 7 . Warfarin exerts its anticoagulant effect by reducing the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase 8 . This protein is encoded by the recently identified vitamin K epoxide reductase complex subunit 1 gene (VKORC1) in which rare mutations associated with clotting factor deficiencies and warfarin resistance have been identified 9 . More recently, genotype for several noncoding polymorphisms in this gene has been shown to influence coumarin anticoagulant dose requirements 10, 11 .
Patients are at greatest risk of over-anticoagulation during the initiation period, with the risk of bleeding being higher during the first few months than later, with the elderly and those carrying mutant CYP2C9 alleles being particularly at risk 12 13, 14 .
These early problems are due principally to the widespread inter-individual variation in response to the warfarin loading dose, explained in part by patient age and genotype.
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From A number of warfarin dosing algorithms 15, 16 and computer generated dosing regimens 17 have been developed with the aim of reducing the risk for patients of over anticoagulation during the initial days of warfarin therapy. Although many of these achieve better outcomes than does dosing using the original and widely used regimen reported by Fennerty et al 18 , particularly amongst the elderly population, early achievement of target INR with avoidance of over anticoagulation remains elusive. Furthermore patients remain, on average, within their target range for only two-thirds of the time 6 .
The current warfarin dosing algorithms do not incorporate genetic and environmental factors which could affect warfarin dose requirements. Knowledge of the extent to which these factors affect anticoagulation response could help in the prediction of a more individualised loading and maintenance warfarin dose for a safer anticoagulation therapy. The aim of the current study was to further characterise the effects of a number of factors that might contribute to the variability in warfarin dose requirements, with the view to developing a novel individualised dosing regimen.
Patients and Methods
Ethical permission for the study was obtained from the Joint University of Newcastle and Health Authority Ethics Committee. Stable patients were recruited from anticoagulation clinics within the Newcastle upon Tyne NHS Trust. A stable patient was defined as one whose warfarin dose requirement had remained constant for at least the three previous clinic visits over a minimum period of 3 months, and The methods used for venous INR measurement, CYP2C9 genotyping and determination of warfarin enantiomer plasma concentrations were as detailed in a previous study 7 . The clearance (CL) for R-and S-warfarin was determined as follows: CL= D/2t . Css.av, in which D is the daily dose of warfarin, t is 24 hours and Css.av is the average steady-state plasma concentration of each warfarin enantiomer, assuming that warfarin bioavailability and compliance is 100% 19 .
VKORC1 (G -1639A) Genotyping
Leukocyte DNA was extracted as described previously 
Results

Patient Characteristics
One hundred and seventy six patients consented to take part in the study. The 121 patients with stable control of anticoagulation recruited from a previous study 7 which used the same selection criteria as the current one were also included in the statistical analysis, giving a total of two hundred and ninety seven patients (cohort 1). The patients' demographics, indications for anticoagulation therapy, genotype and warfarin dose requirements are shown in Table 1 .
VKORC1 genotyping
All samples were genotyped for the G-1639A polymorphism with some also genotyped for an additional intron 1 polymorphism (C1173T) which was previously reported to affect warfarin dose requirement 
Associations with warfarin dose
Median warfarin daily dose requirements varied significantly with gender (2.9 mg females; 3.7 mg, males; p=0.009). Simple correlation analysis of the data revealed that warfarin dose was highly significantly negatively correlated with age (r=-0.40; p=0.0001) and significantly positively correlated with body weight (r=0.21; p=0.003), height (r=0.38; p=0.0001), body surface area (r=0.21; p=0.005), R-warfarin (r=0.56; p=0.0001) and S-warfarin (r=0.57; p=0.0001) enantiomer clearance and total warfarin clearance (r=0.65; p=0.0001).
There was no significant difference in age either between the five CYP2C9, or between the three VKORC1 genotypic groups. The mean warfarin daily dose requirement was 4.08 ± 2.13 mg in CYP2C9 homozygous wild-type patients, which was significantly higher than that in *1/*2 (3.56 ± 1.82 mg, p=0.03), *1/*3 (2.7 ± 1.38 mg, p=0.0001), *2/*2 (1.92 ± 1.12 mg, p=0.02) and *2/*3 and*3/*3 patients 
Warfarin clearance
Stepwise regression was used to evaluate the factors associated with warfarin clearance. Warfarin dose, age, body surface area and CYP2C9 genotype significantly contributed to S-warfarin and total warfarin clearance, whereas only warfarin dose age and body size significantly contributed to R-warfarin clearance. Gender and VKORC1 genotype did not contribute to any of the three regression models for warfarin clearance (table 2) .
Warfarin dosing algorithm
The multivariate regression model including the variables age, CYP2C9 and VKORC1 genotype and height produced the best model for estimating warfarin dose, (table 3) . This novel dosing algorithm was assessed in a second unrelated population of thirty-eight patients on warfarin therapy and with stable control of anticoagulation (cohort 2; see table 1 for details on patient characteristics and demographics). Pearson's correlation analysis of data showed a very close and highly significant relationship between the calculated warfarin dose using the best regression dose model and actual dose (r=0.80; p<0.0001) (figure 2).
The use of the regression model was more likely to underestimate the daily maintenance dose requirements (mean difference = -0.2± 0.8 mg/day).
Discussion
Warfarin therapy, particularly during the initiation period, is associated with a high incidence of over anticoagulation with resultant bleeding, as the inability to take into account inter-and intra-individual variability in response to the drug makes accurate dose predication impossible. This is frequently a cause for concern. It has been estimated that almost half of AF patients who are eligible for, and would benefit from, warfarin therapy are not receiving the drug because of the associated risks and monitoring costs 15 .
We have previously reported on the contribution of CYP2C9 genotype, age and other environmental factors to chronic warfarin dose requirements 7 . In this study, we have extended our previous work to show the impacts of age and CYP2C9 gene in a more representative sample of anticoagulated patients. We have also been able to assess the additional contribution from VKORCI genotype to inter-individual variability, concluding that patient age, height and genetic polymorphism of
CYP2C9 and VKORC1 account for nearly 55% of the variability in warfarin daily
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As with previous studies 7, 21, 22, 23 we found that dose requirements fell with age, decreasing by approximately 0.5-0.7mg per decade between the ages of 20-90 years irrespective of genotype and patient height. Although, the patients were not evenly spread across the eight age decades studied, the sample reflects the distribution by age of anticoagulated patients.
Our results extend the known association between CYP2C9 genotype and daily warfarin dose. There were significant differences in mean dose requirements between each of the variant alleles compared to the wild type. Unfortunately there was only one patient with the genotype *3/*3, despite targeting low dose patients, and therefore the predicted doses for this genotype should be viewed with caution.
We also confirm that carriers of the VKORC1 (-1639) AA genotype require a significantly lower daily dose of warfarin than those carrying the GA or the GG genotypes. Though the VKORC1 gene has only been recently identified, a range of polymorphisms within it have now been described [9] [10] [11] . neither SNP appears functionally significant when assessed using appropriate in vitro assays 10, 11 . An alternative explanation is that polymorphisms situated further upstream or in the 3'-untranslated region but in linkage disequilibrium with G at position -1639 affect levels of VKOR.
Although we demonstrated significant positive correlations between warfarin dose and each of body surface area, weight and height, only the latter made a significant contribution to warfarin dose requirements in the regression model. Despite the significant difference in warfarin dose between male and female patients, gender made no significant contribution to the regression model. However, it is likely that the differences in warfarin dose requirements are attributable to body size, with females in general being smaller than males.
Over 40% of the variability in dose requirements remains unaccounted for. Factors of co-morbidity and, to an extent, concurrent medication were controlled for as these formed part of the exclusion criteria of the study. However, due to the study design, the contributions of vitamin K status and alcohol consumption to warfarin dose requirement were not examined. One study that did examine the influence of vitamin K upon warfarin anticoagulation found that plasma vitamin K concentration was significantly negatively correlated with patient INR 24 . It is unlikely that the impact of vitamin K on warfarin dose requirements would have been realised in this cross-sectional study in patients with stable anticoagulation control since warfarin dose would have already been adjusted in the patients to control for their vitamin K status 7 .
It is also likely that the inter-individual variability in warfarin dose requirements is due, at least in part, to additional genetic factors, including polymorphisms in apolipoprotein E 25 , MDR1 26 , genes encoding vitamin Kdependent clotting factors 27 and possibly genes encoding additional components of the vitamin K epoxide reductase complex 9 .
A significant contributor to the observed variability in dose requirements is interindividual differences in warfarin clearance. As expected, warfarin dose, age, genotype and body surface area had a significant effect on S-warfarin clearance.
These results are thus broadly in concordance with those of previous studies showing that CYP2C9 polymorphisms and age markedly affect S-warfarin clearance and thus warfarin dose requirements 7, 23, 28 . Warfarin dose, age and body surface area were the only significant contributors to the inter-individual variability in Rwarfarin clearance. A recent detailed study found no additional contribution by CYP2C9 upstream polymorphisms to warfarin clearance 20 and, while some additional coding region polymorphisms are known to occur, these are extremely rare in Caucasians. VKORC1 genotype had no effect on warfarin clearance and hence affects warfarin dose requirements through a different mechanism, namely the vitamin K cycle.
In the present study we have shown that incorporation of age, CYP2C9 and VKORC1 genotype and height allow best estimate of warfarin maintenance dose, none of which are taken into account in currently available algorithms. For example, using our regression model, the estimated warfarin daily dose requirement for a 170 cm tall 90 year old patient with CYP2C9*1/*3 and VKORC1-AA genotype is over 6 times lower than that for a 30 year old patient of same height and 
